Skip to content
Late-StageResearch compoundModerate evidence

Emoxypine

Antioxidant medicine (Mexidol) used for stroke and brain blood-vessel disease in Russia; not approved in the EU or the US.

NeuroprotectiveAntioxidantAnxiolyticNeuroprotectionAnxiolyticGABAnoo.affects.antioxidantnoo.affects.anti-inflammatory
Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Pharmacology

ClassNeuroprotection · Anxiolytic
Primary targetInhibition of free-radical lipid peroxidation
Targets4 receptor targets
Half-lifeShort, approximately 2-3 hours orally (the reason for daytime split dosing)
OnsetRoughly 30-60 minutes orally; in clinical use it is dosed 2-3 times per day
EvidenceModerate evidence
Affected systemsGABAnoo.affects.antioxidantnoo.affects.anti-inflammatory

Contents

DETAILED OVERVIEW

What is Emoxypine?

Emoxypine is a compound with antioxidant action. Its version sold as Mexidol is approved as a prescription medicine in Russia and several neighboring countries, mainly for diseases of the brain's blood vessels and for stroke. It is not approved in the European Union, the United Kingdom or the United States, and regulators there have not evaluated it.

It limits the damage that free radicals do to the fats in cell membranes, supports the cells' energy production when oxygen is short, and also affects one of the brain's calming signaling systems (GABA). In placebo-controlled trials in Russia and neighboring countries, recovery improved in the early phase of stroke, but it has no Western approval or evaluation. Mild drowsiness, nausea and dry mouth can occur. It is contraindicated in acute liver or kidney failure, and its safety in pregnancy and breastfeeding is not established.

Mechanism

Antioxidant + membrane stabilizer + GABA-A modulation

Evidence

Russian/CIS human RCTs (stroke); no Western validation

Legal status

Prescription drug in Russia/CIS; not FDA/EMA

Receptor profile

  • Free-radical oxidation / lipid peroxidationStrong
  • Antioxidant enzymes (SOD, glutathione peroxidase)Moderate
  • GABA-A / benzodiazepine receptor complexModerate
  • Cerebral blood flow / mitochondrial ATP productionModerate

Safety

Side effects, stop signs, contraindications

Side effects · 5

  • Mild drowsiness or sedation, especially at higher doses
  • Nausea, dry mouth or mild stomach upset
  • Transient metallic taste, throat irritation or warmth on intravenous administration
  • Rarely, allergic skin reaction (rash, itching)
  • Most human safety data come from Russian/CIS clinical trials; Western regulatory review is lacking

Contraindications · 4

  • Acute liver or kidney failure
  • Pregnancy and breastfeeding: safety not sufficiently established, avoid
  • Known hypersensitivity to pyridine derivatives or to succinate
  • Caution with CNS depressants (additive sedation possible)

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Emoxypine is an antioxidant compound marketed as an approved medicine (Mexidol) in Russia and neighboring countries, used mainly for brain circulation problems and stroke recovery. Clinical studies suggest it can support neurological recovery and daily functioning during the acute and early recovery phases of stroke, and it's also reported to help reduce anxiety. As an antioxidant it protects cells from damage, and it's also used in chronic cerebrovascular disease to support cognition and circulation.

Telegram

Have a question about Emoxypine?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNeuroprotective
FormulaC8H11NO
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.